ARVO 2012 Annual Meeting | May 2012

Preferential Hyperacuity Perimetry Home Monitoring in Patients Following Treatment for Neovascular Age-related Macular Degeneration

Merina Thomas; Shiri Zayit-Soudry; Peggy Orr; Susan B. Bressler; Neil M. Bressler

For patients who had prior anti-VEGF therapy for CNV in which treatment is suspended at a particular visit due to absence of active disease, the preferential hyperacuity perimeter used as a home monitoring device occasionally detected changes warranting resumption of anti-VEGF therapy prior to a routine return visit. However, as a large number of participants had active disease detected at a clinical exam that was not recognized by monitoring, the device would not be acceptable for routine home monitoring in this circumstance without further modification and testing.

Media enquiries? Reach out to our Media Contact